Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects-Reference-Cited by-同舟云学术

Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects

Published:2018-10-25 Issue:1 Volume:368 Page:136-145
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Shen Hong,Holenarsipur Vinay K.,Mariappan T. Thanga,Drexler Dieter M.,Cantone Joseph L.,Rajanna Prabhakar,Singh Gautam Shashyendra,Zhang Yueping,Gan Jinping,Shipkova Petia A.,Marathe Punit,Humphreys W. Griffith

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference38 articles.

1. Elevated plasma vitamers of vitamin B6 in patients with chronic renal failure on regular haemodialysis;Allman;Eur J Clin Nutr,1992

2. Pharmacokinetics/pharmacodynamics of furosemide in man: A review

3. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis;Beringer;Pharmacotherapy,2008

4. Vitamin B6 metabolism in chronic kidney disease--relation to transsulfuration, advanced glycation and cardiovascular disease;Busch;Nephron Clin Pract,2010

5. Pharmacodynamic analysis of the furosemide-probenecid interaction in man

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug transporters in drug disposition – highlights from the year 2023;Drug Metabolism Reviews;2024-09-11

2. Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier;Drug Metabolism Reviews;2024-07-05

3. Expanding Role of Endogenous Biomarkers for Assessment of Transporter Activity in Drug Development: Current Applications and Future Horizon;Pharmaceutics;2024-06-25

4. Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug–Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective;Clinical Pharmacokinetics;2024-06

5. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease;Cells;2024-03-04